Investigation of serum endocan and serglycin levels in obstructive sleep apnea

Kum, Rauf Oğuzhan; Kundi, Fatma Cemre Sazak; Topçuoğlu, Canan; Özcan, Müge

doi:10.1007/s11845-023-03360-3

Cited by 1 publication

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the investigators excluded patients with OSAHS, even though OSAHS may increase endocan levels itself. [26] In the present study, serum and plasma endocan levels were higher in individuals with OSAHS than in controls, and a subgroup analysis according to the severity of the disease, sample type, geographical region, BMI, and study design also revealed similar outcomes. Because endocan is an inflammation-related biomarker and patients with OSAHS are in a state of systemic inflammation due to intermittent hypoxia, endocan levels increase significantly as the severity of OSAHS increases.…”

Section: Discussionsupporting

confidence: 75%

“…Among these 28 studies, 16 were excluded; the reasons for exclusion are listed in Figure 1. Ultimately, 12 studies [17,18,[25][26][27][28][29][30][31][32][33][34] were included in the meta-analysis.…”

Section: Study Inclusionmentioning

confidence: 99%

“…Additionally, 11 studies [17,18,26,27,31,32] comparatively assessed endocan levels in patients with OSAHS and controls. Six studies [17,25,26,28,31,32] addressed the association between endocan levels and AHI, FMD, minimal O 2 saturation, CIMT, and BMI. Moreover, 5 studies [18,[25][26][27][28] reported serum endocan levels as an independent risk factor for OSAHS.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Six studies [17,25,26,28,31,32] addressed the association between endocan levels and AHI, FMD, minimal O 2 saturation, CIMT, and BMI. Moreover, 5 studies [18,[25][26][27][28] reported serum endocan levels as an independent risk factor for OSAHS. All studies had NOS scores ≥ 5.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…The 12 studies ultimately included were published between 2016 and 2023 (Table 1). Five studies [28][29][30]33,34] reported data from samples of the Chinese population, and the remaining 7 [17,18,[25][26][27]31,32] reported data from samples of the Turkish population. Additionally, 11 studies [17,18,26,27,31,32] comparatively assessed endocan levels in patients with OSAHS and controls.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Association between elevated endocan levels and obstructive sleep apnea hypopnea syndrome in Turkey and China: A meta-analysis

He,

Li,

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Endothelial dysfunction has been implicated in the pathogenesis of obstructive sleep apnea–hypopnea syndrome (OSAHS). Previous research has linked endothelial dysfunction to the vascular pathology marker endothelial cell-specific molecule-1 (endocan). This meta-analysis compared endocan concentrations among adult patients with OSAS and controls, and ascertained whether any differences exist. This study aimed to highlight the association between high endocan levels and OSAHS. Methods: A comprehensive, systematic literature search of the PubMed, Cochrane Library, China National Knowledge Infrastructure, Web of Science, Embase, and Wan Fang databases for relevant studies, published between January 2000 and June 10, 2013, was performed. Additionally, standardized mean differences, correlation coefficients, and adjusted odds ratios were used to assess the effect size. Statistical analyses were performed using R version 4.13 (Copenhagen: The Cochrane Collaboration) and Stata version 10.0 (StataCorp LLC, College Station, TX). Results: Twelve studies fulfilled the inclusion criteria. Nine studies reported endocan levels in patients with OSAHS and controls, and 6 reported serum endocan levels in relation to polysomnography (PSG) indexes (apnea-hypopnea index, body mass index, minimum oxygen (O2) saturation, and flow-mediated dilatation [FMD]). Five studies reported that serum endocan levels functioned independently as risk factors for OSAHS. These levels were determined to be elevated in adults with OSAHS compared with controls (standardized mean difference 1.30 [95% confidence interval (CI) 1.06–1.54]) and increased more significantly with increasing disease severity in individuals with OSAHS. Subjects were divided into different subgroups based on race, geographical region, sample type, and study design. Results indicated increased endocan levels across all OSAHS subgroups compared with the control group. The data highlighted a positive association between serum endocan levels and apnea-hypopnea index, and a negative association with FMD and minimum O2 saturation. The overall adjusted odds ratio between serum endocan levels and OSAHS was 1.04 (95% CI 1.02–1.06). Conclusion: Results of this meta-analysis provide further evidence supporting elevated endocan levels in adults with OSAHS. Serum endocan levels were correlated with various PSG indices and may be associated with OSAHS.

show abstract

Section: Discussionsupporting

confidence: 75%